Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

(2014) Norihiro Nishimoto et al.   Modern Rheumatology

Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study

(2014) Eiichi Tanaka et al.   Modern Rheumatology

Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study

(2014) Norihiro Nishimoto et al.   Modern Rheumatology

Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)

(2014) Hisashi Yamanaka et al.   Modern Rheumatology

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study

(2014) Jun Hashimoto et al.   Modern Rheumatology

Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA

(2014) Eiichi Tanaka et al.   Modern Rheumatology

Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK

(2014) Alex Diamantopoulos et al.   PHARMACOECONOMICS

Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: A Markov model based on data from Serbia, country in socioeconomic transition

(2014) Marina Kostic et al.   Vojnosanitetski Pregled

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure

(2013) James R. O'Dell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

(2012) Ronald F van Vollenhoven et al.   LANCET

Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy

(2012) Alexander Diamantopoulos et al.   JOURNAL OF MEDICAL ECONOMICS

Quantifying the economic burden of productivity loss in rheumatoid arthritis

(2011) I. Filipovic et al.   RHEUMATOLOGY

Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis

(2011) E. J. Soini et al.   JOURNAL OF MEDICAL ECONOMICS

The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis

(2010) Graeme Jones   Expert Review of Clinical Immunology

Rheumatoid arthritis

(2010) David L Scott et al.   LANCET

Tocilizumab

(2010) Adith Venkiteshwaran   mAbs

Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA

(2010) A Nakajima et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review

(2010) Gabrielle van der Velde et al.   ARTHRITIS CARE & RESEARCH

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

(2009) Takeru Shiroiwa et al.   HEALTH ECONOMICS

Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice

(2009) Yasuhiko Hirabayashi et al.   RHEUMATOLOGY INTERNATIONAL

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

(2008) N Nishimoto et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease status, costs and quality of life of patients with rheumatoid arthritis in France: The ECO-PR Study

(2008) Gisela Kobelt et al.   JOINT BONE SPINE

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Efficient management of rheumatoid arthritis significantly reduces long-term functional disability

(2007) E Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES